Donald J. Buchsbaum

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

This study shows that entinostat enhances CD8+ T cell responses in tumors but only when administered during a specific window after T cell activation, and this effect can be restored by prior oncolytic virus treatment.

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

This study evaluates the potency and selectivity of the pan-RAS inhibitor ADT-007 in 3D bioprinted organoid tumor models of KRAS-mutant and RAS wild-type colorectal cancer.